- UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum.
- URGN maintains a 100% “Buy” technical opinion from Barchart.
- The company’s revenue is projected to more than double this year and grow by 56% next year. Earnings are estimated to rise by 75% and 263%, respectively.
- Despite five years of revenue growth, URGN remains unprofitable, and short interest stands at 12.76% of float with 9.42 days to cover.